论文部分内容阅读
随着我国加入WTO及世界经济一体化 ,我国在医药流通领域的管制将于 2 0 0 5年全方位放开。本文以全球竞争视野概述了国内外医药流通领域的现状 ,通过我国医药流通领域的代表企业———上海市医药股份有限公司、广州药业股份有限公司、国药集团药业股份有限公司同世界巨头———麦卡森公司 (McKesson)、卡迪诺健康有限公司 (CardinalHealth)在企业的发展历史、赢利模式、绩效评价指标分析等方面的横向比较揭示我国医药流通企业和世界巨头之间的差距 ,并在此基础上提出了我国医药流通从产业组织结构优化角度提出了针对性建议。
With China’s accession to the WTO and the integration of the world economy, China’s control in the field of medicine circulation will be fully liberalized in 2005. This article gives an overview of the current situation in the field of pharmaceutical circulation both at home and abroad through the global competitive perspective. Through the representative enterprises in the field of pharmaceutical circulation in China --- Shanghai Pharmaceutical Co., Ltd., Guangzhou Pharmaceutical Co., Ltd., Sinopharm Pharmaceutical Co., Ltd., --- Horizontal comparison between McKesson and CardinalHealth in the development history, profitability model, performance evaluation index analysis reveals the gap between Chinese medicine circulation enterprises and world giants On this basis, it puts forward that China’s pharmaceutical circulation puts forward pertinent suggestions from the perspective of industrial organization structure optimization.